Using Device Delivering Ophthalmic Solution in a Spray Form Instead of Eye Drops
NCT ID: NCT00565630
Last Updated: 2009-02-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
16 participants
INTERVENTIONAL
2008-01-31
2008-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bioequivalence of Eye Drops and Spray Administration of Vigamox
NCT00666042
Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections
NCT00690313
Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients
NCT01859702
Evaluate The Improvement In Symptoms Of Patients Using Cationorm After Pterygium Surgery
NCT07064187
Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery
NCT00870103
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Aqueous sample will be collected and submitted to a masked laboratory for measuring Vigamox concentration.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Vigamox via the experiemntal device
Vigamox delivered via the device in spray form
Vigamox delivered 4 times, 1 hour prior to cataract surgery
2
Vigamox drops from the commercially available bottles
Vigamox delivered via the device in spray form
Vigamox delivered 4 times, 1 hour prior to cataract surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vigamox delivered via the device in spray form
Vigamox delivered 4 times, 1 hour prior to cataract surgery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Advanced Ophthalmic Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dept. of Ophthalmology, TAMC, Tel Aviv, Israel
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adi Michaeli, MD
Role: PRINCIPAL_INVESTIGATOR
Dept of Ophthalmology, TAMC, Tel Aviv, Israel
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TAMC 06-306
Identifier Type: -
Identifier Source: secondary_id
Drops vs. spray administration
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.